文献速递慢性肾脏病

SONAR试验事后分析:阿曲生坦与2型糖尿病合并CKD患者疼痛减少相关

Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
PubMed 文献 · Kidney Int · 2023-08-31

SONAR试验事后分析评估内皮素受体拮抗剂阿曲生坦与疼痛及镇痛药处方的关联。该随机双盲安慰剂对照试验纳入2型糖尿病合并CKD患者(eGFR 25-75 ml/min/1.73 m2;UACR 300-5000 mg/g),阿曲生坦组与安慰剂组各1834例。中位随访2.2年,阿曲生坦组首次疼痛相关不良事件发生率低于安慰剂组(138.2 vs 170.2/1000人年,HR 0.82 [95%CI 0.72-0.93]),且镇痛药启动更少(HR 0.72 [95%CI 0.60-0.88])。

要点

  • 阿曲生坦组首次疼痛相关不良事件发生率138.2/1000人年,安慰剂组170.2/1000人年,HR 0.82(95%CI 0.72-0.93)。
  • 阿曲生坦减少所有(首次及后续)疼痛相关不良事件,率比0.80(95%CI 0.70-0.91)。
  • 阿曲生坦组启动镇痛药(包括NSAIDs和阿片类)少于安慰剂组,HR 0.72(95%CI 0.60-0.88)。

核心结论

  • 在严格选择的2型糖尿病合并CKD患者中,阿曲生坦与疼痛相关事件及疼痛相关镇痛药使用减少相关。

研究设计与样本

  • SONAR试验事后分析;随机双盲安慰剂对照试验,纳入2型糖尿病合并CKD患者(eGFR 25-75 ml/min/1.73 m2;UACR 300-5000 mg/g),阿曲生坦组与安慰剂组各1834例。

主要发现

  • 中位随访2.2年,共发生1183例疼痛相关不良事件。
  • 首次疼痛相关事件发生率:阿曲生坦组138.2/1000人年 vs 安慰剂组170.2/1000人年,HR 0.82(95%CI 0.72-0.93)。
  • 所有(首次及后续)疼痛相关不良事件率比0.80(95%CI 0.70-0.91)。
  • 考虑死亡竞争风险后结果相似,sub-hazard ratio 0.81(95%CI 0.71-0.92)。
  • 随访期间阿曲生坦组启动镇痛药(包括NSAIDs和阿片类)少于安慰剂组,HR 0.72(95%CI 0.60-0.88)。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pain is prevalent among patients with diabetes and chronic kidney disease (CKD). The management of chronic pain in these patients is limited by nephrotoxicity of commonly used drugs including non-steroidal anti-inflammatory drugs (NSAIDs) and opioids. Since previous studies implicated endothelin-1 in pain nociception, our post hoc analysis of the SONAR trial assessed the association between the endothelin receptor antagonist atrasentan and pain and prescription of analgesics. SONAR was a randomized, double-blind, placebo-controlled clinical trial that recruited participants with type 2 diabetes and CKD (estimated glomerular filtration rate 25-75 ml/min/1.73 m2; urinary albumin-to-creatinine ratio 300-5000 mg/g). Participants were randomized to receive atrasentan or placebo (1834 each arm). The main outcome was pain-related adverse events (AEs) reported by investigators. We applied Cox regression to assess the effect of atrasentan compared to placebo on the risk of the first reported pain-related AE and, secondly, first prescription of analgesics. We used the Anderson-Gill method to assess effects on all (first and subsequent) pain-related AEs. During 2.2-year median follow-up, 1183 pain-related AEs occurred. Rates for the first pain-related event were 138.2 and 170.2 per 1000 person-years in the atrasentan and placebo group respectively (hazard ratio 0.82 [95% confidence interval 0.72-0.93]). Atrasentan also reduced the rate of all (first and subsequent) pain-related AEs (rate ratio 0.80 [0.70-0.91]). These findings were similar after accounting for competing risk of death (sub-hazard ratio 0.81 [0.71-0.92]). Patients treated with atrasentan initiated fewer analgesics including NSAIDs and opioids compared to placebo during follow-up (hazard ratio = 0.72 [0.60-0.88]). Thus, atrasentan was associated with reduced pain-related events and pain-related use of analgesics in carefully selected patients with type 2 diabetes and CKD.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Chan KW, Smeijer JD, Schechter M, et al. Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease. Kidney Int. 2023. PMID: 37657768. doi:10.1016/j.kint.2023.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。